FDA Accepts ANI’s Refiled Cortophin Gel

For Indications Including Multiple Sclerosis, Rheumatoid Arthritis And Nephrotic Syndrome

 
• By Akriti Seth
  
Approval
After refusing the application last year, the FDA has accepted ANI’s refiled Cortophin Gel sNDA • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin